Investor Relations

Press Release

iCo Therapeutics to Present at EPIC in London, England

June 20, 2006

VANCOUVER, Canada- iCo Therapeutics Inc. announced today that Andrew Rae, iCo’s Chief Executive Officer, will present at EPIC, a European Partnering and Investment Conference taking place June 22nd at the Cumberland Hotel in London, England.

EPIC is a biotechnology conference which showcases over 60 UK and European biotechnology companies. EPIC presents growing biotechnology companies an excellent opportunity to speak to an audience of potential partners, investors and professional advisors that could help to further develop their companies.

“EPIC is an excellent forum to promote the Company’s progress with iCo-007, the first product in our ocular franchise, as well as explore new financing opportunities. We are pleased to have been invited to present before such an influential community,” stated Mr. Rae.

Mr. Rae’s presentation will take place on Thursday, June 22nd at 2:00 pm. For more information on EPIC, visit the conference website at http://www.epicbiotech.com.

About iCo Therapeutics Inc.

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products, iCo-007, in Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies, and iCo-009, a oral reformulation of Amphotericin B for sight and life – threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenterally administered drugs to the oral route of administration.

iCo Therapeutics trades on the TSX-Venture exchange under the symbol “ICO”.

No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics’ current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Business Development Contact:
Dr. John Clement, CBO
604.602.9414 × 222

Finance Contact:
Mr. John Meekison, CFO
604.602.9414 × 224

Investor Contact:
Frederica Bell, Director, Corporate Development
604.602.9414 × 228

Investor Relations

Press Release

Investor & Media Contact

Contact Us